

See differences between formulations that apparatus 1 and 2 won't show.



SOTAX CE 7smart USP apparatus 4

The Flow-Through dissolution method is approved for use and accepted by the FDA and USP for a wide range of formulations and applications including:

Small Volume Dissolution • IVIVC Studies • XR/MR Solid Dose • APIs, Powders, Granules
Injectable Suspensions • Poorly Soluble Compounds • Soft Gels • Suppositories • Implants
Stents • Drug Coated Medical Devices • Liposomes • Microspheres • Nanoparticles

SOTAX India Pvt. Ltd.

601, ECO House
Vishweshwar Nagar
Goregaon East
Mumbai 400063

phone: +91-22-42950191/92
fax: +91-22-40141332
sotaxindia@sotax.com
www.sotax.com

SOTAX
Solutions for Pharmaceutical Testing



On 26th & 27th July, 2016
Venue : Courtyard by Marriott, Ahmedabad

Programme Schedule

Disso India 2016 Programme

SESSION	TIME	NAME OF SPEAKER	TOPIC OF TALK
DAY 1 : 26/07/2016			
	08.30 a.m. - 09.30 a.m.	Registration	
	09.30 a.m. - 10.30 a.m.	Inaugural Session	
10.30 a.m. - 11.15 a.m. TEA BREAK			
SESSION I	11.15 a.m. - 12.00 p.m.	Dr. Vinod Shah <i>Ex-US FDA, Maryland, USA</i>	Regulatory updates: What is new in BCS and Biowaivers?
SESSION II	12.00 p.m. - 12.45 p.m.	Mr. H G Koshia <i>Commissioner FDCA, Gujarat</i>	“Dissolution Testing- An Indian Regulators perspective”
12.45 p.m. - 02.00 p.m. LUNCH BREAK			
SESSION III	02.00 p.m. - 02.45 p.m.	Prof. Padma V. Devarajan <i>Professor in Pharmacy, ICT, Mumbai</i>	“Dissolution Testing during Product Development”
SESSION IV	02.45 p.m. - 03.30 p.m.	Dr. Vincent Jannin <i>Gattefosse</i>	“Combined <i>In vitro</i> Dispersion / Digestion Technique to Assay the Solubility Enhancement of Poorly Soluble Drugs: New Case Studies with Gelucire 48/16.”
03.30 p.m. - 04.00 p.m. TEA BREAK			
SESSION V	04.00 p.m. - 04.45 p.m.	Dr. Abhijit V. Gothosjkar <i>Technical Advisor, Anshul Life Sciences, Mumbai</i>	“Role of excipients in dissolution”
SESSION VI	04.45 p.m. - 05.30 p.m.	Dr. Umesh Banakar <i>Founder President, Banakar Consulting Services, USA</i>	“Challenges in meeting regulatory requirements for IVIVC – Case studies with examples.”

Disso India 2016 Programme

SESSION	TIME	NAME OF SPEAKER	TOPIC OF TALK
DAY 2 : 27/07/2016			
SESSION I	09.30 a.m. - 10.15 a.m.	Dr. Umesh Banakar Founder President, Banakar Consulting Services, USA	“Dissolution Testing and Intellectual Property:”
SESSION II	10.15 a.m. - 11.00 a.m.	Mr. Samir Haddouchi Managing Director, SPS Pharma, Orleans, France.	“Regulatory applications in area of drug release using flow through apparatus.”
11.00 a.m. - 11.30 a.m. TEA BREAK			
SESSION III	11.30 a.m. - 12.15 p.m.	Prof. Mukesh Gohel Research Director, Anand Pharmacy College, Gujarat	“Study on combined influence of alcohol and food on the <i>in vitro</i> performance of modified release dosage forms”
SESSION IV	12.15 p.m. - 01.00 p.m.	Mr. Vijay Kshirsagar Director, TRAC Pharma Consulting, Navi Mumbai	“QbD approach in Dissolution Method Development”
01.00 p.m. - 02.00 p.m. LUNCH BREAK			
SESSION V	02.00 p.m. - 02.45 p.m.	Prof. Mangal S. Nagarsenkar HOD, Pharmaceutics, BCP, Mumbai	“Challenges in conducting drug release studies from nanomedicines.”
SESSION VI	02.45 p.m. - 03.30 p.m.	Dr. Vinod P Shah Ex-US FDA, Maryland, USA	“Have we Reached the Limits of using Dissolution Tests in Pharmaceutical Industry?”
03.30 p.m. - 04.00 p.m. TEA BREAK			
04.00 p.m. - 04.45 p.m. PANEL DISCUSSION & CONCLUDING REMARKS			

• PLATINUM PARTNER •

sotax
Solutions for Pharmaceutical Testing

• SCIENTIFIC SESSION PARTNERS •


Anshul Life Sciences
Partnering innovation, adding value.


GATTEFOSSÉ

• DELEGATE KIT PARTNER •

 PALL Life Sciences

• CONFERENCE PARTNERS •

Minitab  Qsutra

 bio.com